Ticagrelor versus Clopidogrel After Left Main Coronary Artery Disease Intervention

This publication has 7 references indexed in Scilit:

• 2024 ESC Guidelines for the management of chronic coronary syndromes (Translation of the shortened document prepared by the Czech Interventional Cardiology Association of the Czech Society of Cardiology)
  Cor et Vasa, 2025
• Ticagrelor versus Clopidogrel in Patients with left main Coronary Artery Stenting
  Cardiovascular Drugs and Therapy, 2024
• New Insights Into Long- Versus Short-Term Dual Antiplatelet Therapy Duration in Patients After Stenting for Left Main Coronary Artery Disease: Findings From a Prospective Observational Study
  Circulation: Cardiovascular Interventions, 2022
• Management of Antithrombotic Therapy after Acute Coronary Syndromes
  New England Journal of Medicine, 2021
• Clinically Significant Bleeding With Ticagrelor Versus Clopidogrel in Korean Patients With Acute Coronary Syndromes Intended for Invasive Management
  Circulation, 2019
• Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
  New England Journal of Medicine, 2009
• Benefit of a 600-mg Loading Dose of Clopidogrel on Platelet Reactivity and Clinical Outcomes in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome Undergoing Coronary Stenting
  JACC, 2006